AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

Wren isn’t the only bull at Wells Fargo. Biotech expert and analyst Derek Archila is setting his sights on two stocks poised for massive gains – one of which could soar by as much as ~440%. If ...

Experts say the research will divert funding to confirm what decades of research have already shown. HealthDay News — The U.S. Centers for Disease Control and Prevention (CDC) is preparing to study ...

Among the 63% of patients with generalized pustular psoriasis who experienced a flare, patients were more likely to be women, younger, and have more active disease. Generalized pustular psoriasis (GPP ...

The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate ...

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? SAN ...

They have forged a global license deal to develop and commercialize IL-36R antagonist monoclonal antibody imsidolimab, which has completed two global phase 3 trials for a rare form of the autoimmune ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Hybrid closed-loop insulin delivery does not affect rate of severe hypoglycemia and increases rate of ketoacidosis. HealthDay News — For young people with type 1 diabetes, hybrid closed-loop ...